Literature DB >> 8873515

The substance-using human immunodeficiency virus patient: approaches to outpatient management.

P G O'Connor1, J H Samet.   

Abstract

Individuals with a substance use disorder who are infected with human immunodeficiency virus (HIV) provide physicians with challenging issues for both medical management and drug treatment. Using a case presentation format, we present an overview of some of the major issues involved in delivering effective primary care for these individuals. A detailed medical and substance use history is critical to sort common complaints that can be seen both in HIV infection and with drug use. Physicians must be able to recognize withdrawal syndromes and differentiate those signs and symptoms that may be attributed to specific drugs. A two-phase model of drug abuse treatment takes into account both detoxification and maintenance of abstinence. Primary care physicians should be able to initiate the process of substance abuse treatment and refer the patient to appropriate substance abuse programs when necessary. Pharmacological approaches to long-term abstinence with heroin addiction include methadone, LAAM, and naltrexone. While clinically challenging, HIV-infected substance users can be successfully managed using the general principles of primary care.

Entities:  

Mesh:

Year:  1996        PMID: 8873515     DOI: 10.1016/S0002-9343(96)00200-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Adherence to combination antiretroviral therapies in HIV patients of low health literacy.

Authors:  S C Kalichman; B Ramachandran; S Catz
Journal:  J Gen Intern Med       Date:  1999-05       Impact factor: 5.128

2.  The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.

Authors:  James E Egan; Paul Casadonte; Tracy Gartenmann; Judith Martin; Elinore F McCance-Katz; Julie Netherland; John A Renner; Linda Weiss; Andrew J Saxon; David A Fiellin
Journal:  J Gen Intern Med       Date:  2010-05-11       Impact factor: 5.128

3.  Factors affecting willingness to provide buprenorphine treatment.

Authors:  Julie Netherland; Michael Botsko; James E Egan; Andrew J Saxon; Chinazo O Cunningham; Ruth Finkelstein; Mark N Gourevitch; John A Renner; Nancy Sohler; Lynn E Sullivan; Linda Weiss; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2008-08-20

4.  Illness burden mediates the relationship between pain and illicit drug use in persons living with HIV.

Authors:  Jennie C I Tsao; Aram Dobalian; Judith A Stein
Journal:  Pain       Date:  2005-11-16       Impact factor: 7.926

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.